Past Event! Note: this event has already taken place.

Christopher Wild: The Global Cancer Burden

November 6, 2015 at 3:00 PM to 5:00 PM

Location:5050 Minto Centre

Reception to follow.

Free to All. But Seating is Limited. Please Register Here

The Event – The Global Cancer Burden: Necessity is the Mother of Prevention
Dr. Christopher Wild will discuss the escalating number of cancers worldwide, what we can do for prevention and early detection, as well as how we might bring the modern molecular sciences to bear on this problem.

The Speaker – Dr. Christopher Wild is the Director of the International Agency for Research on Cancer (IARC).

IARC is the cancer agency of the World Health Organization (WHO), having been established in 1965 by a resolution of the World Health Assembly. The objective of IARC is to promote international collaboration in cancer research. Today, IARC’s membership has grown to 24 countries, including Canada. The Agency’s work generates evidence for cancer prevention around the globe. More specifically IARC describes the occurrence of cancer, identifies its causes and evaluates strategies for prevention and early detection, including their implementation in health care settings. The Agency also has a commitment to training cancer researchers worldwide.

The Governing Council elects IARC’s Director, who normally serves for a 5-year term. The Council elected Dr. Christopher Wild, who took office on 1 January 2009. Dr Wild was re-elected in 2013 for a second 5-year term. Dr. Wild’s specialty is molecular epidemiology, and he has a background in oncology (PhD, Univ. of Manchester) and pharmacology (BSc, Univ. of Manchester). Dr. Wild’s main research interest is the interplay between environmental, lifestyle and genetic risk factors in the causation of human cancer. Dr Wild developed the concept of the exposome, emphasizing the need for improved measurement of environmental and lifestyle exposures to complement the advances in genome research, in order to better understand the causes and prevention of human cancer.

This event is co-sponsored by the Technology Innovation Management Program, and the Offices of the Provost & Vice-President (Academic), and of the Vice-President (Research & International), Carleton University.